Background: Near-infrared (NIR) imaging with indocyanine green (ICG)-enhanced fluorescence is widely used in laparoscopic surgery. This study aimed to evaluate this technique's feasibility and usefulness in intraoperatively assessing vascular perfusion in a laparoscopically harvested omental flap.

Materials And Surgical Techniques: From March 2015 to February 2016, we prospectively evaluated patients undergoing breast cancer surgery followed by immediate breast reconstruction using a laparoscopically harvested omental flap. After laparoscopic preparation of the pedicled graft, the perfusion area of the omental graft was evaluated by using intraoperative Doppler ultrasonography and NIR imaging with intravenous ICG injection. Graft viability was evaluated by using Doppler ultrasonography 2 days postoperatively; for cosmetic outcome, Breast Cancer Conservative Treatment Cosmetic Results software was used 1 month postoperatively.

Discussion: The laparoscopic harvesting of an omental flap was successfully performed in eight patients without conversion to open surgery. The mean time to the initial detection of ICG-enhanced fluorescence uptake was 3.25 ± 1.16 minutes. On intraoperative Doppler ultrasonography, a pulseless area ≥10% was detected in five patients (62.5%). However, NIR imaging revealed no patients had an ischemic portion ≥10%. There were no ICG-related intraoperative or postoperative complications. All patients showed patent vessels on Doppler ultrasonography 2 days postoperatively. Cosmetic outcomes were mostly favorable 1 month postoperatively. The Breast Cancer Conservative Treatment Cosmetic Results evaluation 1 month postoperatively showed excellent, good, and fair results, with no poor scores. With regard to vascular perfusion, ICG-enhanced NIR imaging is a feasible and useful tool for harvesting a laparoscopic omental flap in breast cancer patients.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ases.12709DOI Listing

Publication Analysis

Top Keywords

breast cancer
20
omental flap
16
nir imaging
16
doppler ultrasonography
16
laparoscopic omental
8
flap breast
8
icg-enhanced fluorescence
8
vascular perfusion
8
laparoscopically harvested
8
harvested omental
8

Similar Publications

Management of nausea and vomiting induced by antibody-drug conjugates.

Breast Cancer

January 2025

Advanced Cancer Translational Research Institute, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.

Antibody-drug conjugates (ADCs) are an emerging class of anticancer therapy that combines the specificity and long circulation half-life of monoclonal antibodies with the cytotoxic potency of the payload connected through a chemical linker. The optimal management of toxicities is crucial for improving quality of life in patients undergoing ADCs and for avoiding improper dose reductions or discontinuations. This article focuses on the characteristics and management of nausea and vomiting (NV) induced by three ADCs: trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd).

View Article and Find Full Text PDF

Purpose: Trophoblast cell-surface antigen 2 (Trop2) is overexpressed in various solid tumors and contributes to tumor progression, while its expression remains low in normal tissues. Trop2-targeting antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen. Leveraging the enhanced specificity of ADCs, we conducted the first immunoPET imaging study of Trop2 expression in gastric cancer (GC) and triple-negative breast cancer (TNBC) models using Zr-labeled Trodelvy ([Zr]Zr-DFO-Trodelvy).

View Article and Find Full Text PDF

Background: Breast carcinoma stands out as the most widespread invasive cancer and the top contributor to cancer-related mortality in women. Nanoparticles have emerged as promising tools in cancer detection, diagnosis, and prevention. In this study, the antitumor and apoptotic capability of silver nanoparticles synthesized through Scrophularia striata extract (AgNPs-SSE) was investigated toward breast cancer cells.

View Article and Find Full Text PDF

SHP2 promotes the epithelial-mesenchymal transition in triple negative breast cancer cells by regulating β-catenin.

J Cancer Res Clin Oncol

January 2025

Key Laboratory of Laboratory Medicine, Ministry of Education of China, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.

Purpose: Growing evidence suggests that the tyrosine phosphatase SHP2 is pivotal for tumor progression. Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer, characterized by its high recurrence rate, aggressive metastasis, and resistance to chemotherapy. Understanding the mechanisms of tumorigenesis and the underlying molecular pathways in TNBC could aid in identifying new therapeutic targets.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!